Connecting Innovation to Purpose

Emerging clinical-stage competition is not solving for existing challenges 11 Seagen astellas PadcevⓇ 1.25 mg/kg ¹ 1 D1, D8, D15/28 days 51% (n=155) ² 2 38% 25% 5% 3 Bicycle 34% 64% Limitation Upper dose limit Schedule ≥ Grade 3 AE rate Peripheral neuropathy Skin reactions Neutropenia (Gr 3) Dose reduction Dose interruptions 1 Rosenberg, et al., "EV-101 JCO, 2020 Apr 1; 38(10): 1041-1049, 2. Powles et al., EV-301 2021, 3. Zhang et al., ESMO 2023, 4 Rigby et al., 2023, 6 Bicycle corporate deck Nov 2023 # - combined frequency of Grade 3 neutropenia/ low neutrophil count BT8009 5 mg/m² Q1W 65% (n=20) 6 30% 10% 10% # 16% 24% Mabwell 迈威生物 4 9MW-2821 1.25 mg/kg ³ D1, D8, D15 /28 days 3 35% (n=85) ³ 17% 18% 19% 3.5% 28%

View entire presentation